Modulation of the TRPV4 ion channel as a therapeutic target for disease
- PMID: 28202366
- DOI: 10.1016/j.pharmthera.2017.02.019
Modulation of the TRPV4 ion channel as a therapeutic target for disease
Abstract
Transient Receptor Potential Vanilloid 4 (TRPV4) is a broadly expressed, polymodally gated ion channel that plays an important role in many physiological and pathophysiological processes. TRPV4 knockout mice and several synthetic pharmacological compounds that selectively target TRPV4 are now available, which has allowed detailed investigation in to the therapeutic potential of this ion channel. Results from animal studies suggest that TRPV4 antagonism has therapeutic potential in oedema, pain, gastrointestinal disorders, and lung diseases such as cough, bronchoconstriction, pulmonary hypertension, and acute lung injury. A lack of observed side-effects in vivo has prompted a first-in-human trial for a TRPV4 antagonist in healthy participants and stable heart failure patients. If successful, this would open up an exciting new area of research for a multitude of TRPV4-related pathologies. This review will discuss the known roles of TRPV4 in disease, and highlight the possible implications of targeting this important cation channel for therapy.
Keywords: Gastrointestinal disease; Inflammation; Oedema; Pain; Respiratory disease; TRPV4; Vascular tone.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
TRPV4: physiological role and therapeutic potential in respiratory diseases.Naunyn Schmiedebergs Arch Pharmacol. 2015 Apr;388(4):421-36. doi: 10.1007/s00210-014-1058-1. Epub 2014 Oct 24. Naunyn Schmiedebergs Arch Pharmacol. 2015. PMID: 25342095 Review.
-
Modulation of TRPV4 by diverse mechanisms.Int J Biochem Cell Biol. 2016 Sep;78:217-228. doi: 10.1016/j.biocel.2016.07.012. Epub 2016 Jul 15. Int J Biochem Cell Biol. 2016. PMID: 27425399 Review.
-
An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure.Sci Transl Med. 2012 Nov 7;4(159):159ra148. doi: 10.1126/scitranslmed.3004276. Sci Transl Med. 2012. PMID: 23136043
-
TRPV4: new therapeutic target for inflammatory bowel diseases.Biochem Pharmacol. 2014 May 15;89(2):157-61. doi: 10.1016/j.bcp.2014.01.005. Epub 2014 Jan 16. Biochem Pharmacol. 2014. PMID: 24440740 Review.
-
The transient receptor potential vanilloid 4 (TRPV4) ion channel mediates protease activated receptor 1 (PAR1)-induced vascular hyperpermeability.Lab Invest. 2020 Aug;100(8):1057-1067. doi: 10.1038/s41374-020-0430-7. Epub 2020 Apr 27. Lab Invest. 2020. PMID: 32341518 Free PMC article.
Cited by
-
Promoting Articular Cartilage Regeneration through Microenvironmental Regulation.J Immunol Res. 2024 Jul 26;2024:4751168. doi: 10.1155/2024/4751168. eCollection 2024. J Immunol Res. 2024. PMID: 39104594 Free PMC article. Review.
-
Novel Analgesics with Peripheral Targets.Neurotherapeutics. 2020 Jul;17(3):784-825. doi: 10.1007/s13311-020-00937-z. Epub 2020 Oct 15. Neurotherapeutics. 2020. PMID: 33063247 Free PMC article. Review.
-
Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment.Front Pharmacol. 2023 Jun 30;14:1211719. doi: 10.3389/fphar.2023.1211719. eCollection 2023. Front Pharmacol. 2023. PMID: 37456742 Free PMC article. Review.
-
TRPV4 Activation and its Intracellular Modulation Mediated by Kinin Receptors Contribute to Painful Symptoms Induced by Anastrozole.Mol Neurobiol. 2024 Mar;61(3):1627-1642. doi: 10.1007/s12035-023-03654-8. Epub 2023 Sep 23. Mol Neurobiol. 2024. PMID: 37740866
-
Structural Pharmacology of TRPV4 Antagonists.Adv Sci (Weinh). 2024 Jul;11(25):e2401583. doi: 10.1002/advs.202401583. Epub 2024 Apr 24. Adv Sci (Weinh). 2024. PMID: 38659239 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases